GO:0019992 diacylglycerol binding: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0019992 (diacylglycerol binding) is a molecular function defined as binding to a diacylglycerol, a diester of glycerol and two fatty acids.
• The C1 domain is the prototypical diacylglycerol-binding module, but DAG binding also occurs through other domains such as the PAT domain of perilipin 3.
• Diacylglycerol binding proteins include diacylglycerol kinases (DGKs), protein kinase C (PKC) isoforms, chimaerins, Munc13, and perilipins.
• DAG binding regulates diverse processes including signal transduction, insulin sensitivity, dendritic morphology, and synaptic vesicle priming.
• Dysregulated DAG binding and DAG signaling are implicated in obesity-induced insulin resistance, cancer, and neurological disorders.
• CRISPR-based models (knockout, point mutation, knock-in, overexpression) enable causal interrogation of DAG-binding proteins in health and disease.
Description
Diacylglycerol (DAG) is a neutral lipid that serves as both a metabolic intermediate and a critical second messenger in eukaryotic cells. The binding of DAG to specific protein domains is a fundamental molecular event that translates lipid signals into cellular responses. GO:0019992, diacylglycerol binding, captures this molecular function, defined as binding to a diacylglycerol, a diester of glycerol and two fatty acids. This term is essential for annotating proteins that directly interact with DAG, including diacylglycerol kinases, protein kinase C isoforms, and other effectors. Researchers study diacylglycerol binding to understand how lipid second messengers control processes such as cell proliferation, differentiation, insulin signaling, and synaptic transmission. The C1 domain is the most well-characterized DAG-binding module, but recent work has revealed additional DAG-binding domains, such as the PAT domain of perilipin 3, expanding the repertoire of DAG effectors. Given the broad physiological and pathological relevance of DAG signaling, precise annotation of diacylglycerol binding is critical for functional genomics, drug discovery, and the development of targeted therapies for metabolic and neurological diseases.
diacylglycerol binding At A Glance
| GO ID | GO:0019992 |
|---|---|
| GO term | diacylglycerol binding |
| Ontology | molecular_function |
| Synonym | none |
| Definition | Binding to a diacylglycerol, a diester of glycerol and two fatty acids. |
| Major function | Mediates lipid second messenger signaling by recruiting and activating DAG-responsive proteins. |
| Representative domains | C1 domain, PAT domain, and other DAG-binding modules. |
| Key protein families | Diacylglycerol kinases, protein kinase C, chimaerins, Munc13, perilipins. |
| Associated diseases | Obesity-induced insulin resistance, cancer, neurological disorders. |
What Is GO:0019992?
GO:0019992 diacylglycerol binding is a molecular function term describing the selective interaction of a protein or domain with a diacylglycerol molecule, which is a diester of glycerol and two fatty acids. This binding event is non-covalent and reversible, and it typically mediates membrane recruitment, conformational changes, or allosteric regulation of the binding protein.
Why Is diacylglycerol binding Important in Cell Biology?
Diacylglycerol binding is a central node in lipid signaling, linking membrane lipid metabolism to protein function and cellular behavior. It is essential for understanding how cells decode DAG signals to regulate insulin sensitivity, synaptic plasticity, and cell growth. Moreover, DAG-binding proteins are emerging as therapeutic targets, as exemplified by allosteric activators of DGKQ that ameliorate insulin resistance.
• DAG binding is a key mechanism for recruiting cytosolic proteins to membranes, thereby initiating signaling cascades.
• It regulates insulin sensitivity through the sn-1,2-DAG-PKCε axis, a pathway implicated in obesity-induced insulin resistance.
• DAG-binding proteins such as α1-chimaerin control dendritic morphology, affecting neuronal connectivity.
• Munc13-1 activation by DAG is critical for synaptic vesicle priming and neurotransmitter release.
• Perilipin 3 binds DAG via its PAT domain, linking lipid droplets to DAG metabolism.
• Diacylglycerol kinases terminate DAG signaling by phosphorylating DAG to phosphatidic acid, and their activity depends on DAG binding.
• Dysregulated DAG signaling is associated with cancer, diabetes, and neurological disorders.
• Understanding DAG binding facilitates the design of drugs targeting lipid signaling pathways.
• GO:0019992 enables functional annotation of genomes and proteomes in the context of lipid signaling.
• CRISPR screens can identify novel DAG-binding proteins and their roles in disease.
What Happens During diacylglycerol binding?
Membrane recruitment and conformational change
In simple terms: When a protein binds DAG, it often moves to the cell membrane and changes shape to become active.
Many DAG-binding proteins, such as protein kinase C and chimaerins, contain a C1 domain that specifically recognizes DAG within membranes. Binding of DAG to the C1 domain induces a conformational change that relieves autoinhibition and promotes membrane association, allowing the protein to interact with downstream effectors. This recruitment is essential for signal propagation.
Allosteric activation of enzymes
In simple terms: DAG binding can switch on enzymes by changing their active site.
For diacylglycerol kinases (DGKs), DAG binding is not only for membrane targeting but also for allosteric activation. For example, DGKQ is activated by DAG, and small-molecule allosteric activators of DGKQ have been shown to ameliorate insulin resistance by modulating the sn-1,2-DAG-PKCε signaling axis. Similarly, Munc13-1 is activated by DAG-lactones, which mimic DAG and enhance synaptic vesicle priming.
Modulation of protein-protein interactions
In simple terms: DAG binding can change which other proteins a protein talks to.
Beyond membrane recruitment, DAG binding can expose or mask protein-protein interaction surfaces. The C1 domain, for instance, can switch from DAG binding to protein-protein interactions, thereby diversifying signaling outcomes. This dual functionality allows DAG-binding proteins to integrate lipid and protein signals.
Regulation of lipid droplet dynamics
In simple terms: Some proteins bind DAG on lipid droplets to control fat storage.
Perilipin 3, a lipid droplet-associated protein, binds DAG via conserved residues in its PAT domain. This interaction is important for lipid droplet formation and turnover, linking DAG binding to cellular lipid storage and metabolism.
Termination of DAG signaling
In simple terms: DAG kinases bind DAG and convert it to another lipid, stopping the signal.
Diacylglycerol kinases (DGKs) bind DAG and phosphorylate it to phosphatidic acid, thereby terminating DAG-mediated signals. This enzymatic activity is dependent on DAG binding and is crucial for resetting signaling pathways.
Key Genes Involved in GO:0019992 diacylglycerol binding
The following genes encode proteins that directly bind diacylglycerol and mediate its biological effects.
| Gene | Major Role | Research Relevance |
|---|---|---|
| DGKA | Diacylglycerol kinase alpha; phosphorylates DAG to phosphatidic acid | Regulates T-cell signaling and cancer |
| DGKQ | Diacylglycerol kinase theta; allosteric activation by DAG | Target for insulin resistance; allosteric activators discovered |
| DGKZ | Diacylglycerol kinase zeta; contains PDZ-binding motif | Implicated in synaptic signaling and cancer |
| PRKCA | Protein kinase C alpha; C1 domain binds DAG | Central to many signaling pathways; cancer |
| PRKCE | Protein kinase C epsilon; DAG-activated | Mediates insulin resistance in obesity |
| CHN1 | Alpha1-chimaerin; DAG-binding protein | Regulates dendritic morphology |
| CHN2 | Beta2-chimaerin; DAG-binding protein | Involved in neuronal development |
| UNC13A | Munc13-1; DAG-activated synaptic vesicle priming factor | Essential for neurotransmitter release |
| UNC13B | Munc13-2; DAG-binding protein | Synaptic transmission |
| PLIN3 | Perilipin 3; PAT domain binds DAG | Lipid droplet biology |
| PLIN2 | Perilipin 2; related to PLIN3 | Lipid storage |
| RASGRP1 | Ras guanyl releasing protein 1; C1 domain binds DAG | T-cell signaling |
| RASGRP2 | Ras guanyl releasing protein 2; C1 domain binds DAG | Platelet function |
| RASGRP3 | Ras guanyl releasing protein 3; C1 domain binds DAG | B-cell signaling |
| RASGRP4 | Ras guanyl releasing protein 4; C1 domain binds DAG | Myeloid signaling |
| MCF2 | Dbl; DAG-binding protein | Cytoskeletal regulation |
| ARHGAP1 | Rho GTPase activating protein 1; DAG-binding | Cytoskeletal dynamics |
How Is diacylglycerol binding Regulated?
Diacylglycerol binding is regulated by the local concentration of DAG in membranes, which is controlled by phospholipase C (PLC) and diacylglycerol kinases (DGKs). PLC generates DAG from phosphatidylinositol 4,5-bisphosphate, while DGKs phosphorylate DAG to phosphatidic acid, terminating its signaling. Additionally, protein phosphorylation and lipid environment can modulate the affinity of DAG-binding domains. For example, the activity of DGKQ is regulated by allosteric activators that enhance its DAG binding and catalytic activity.
diacylglycerol binding and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| DGKQ | Obesity-induced insulin resistance | Knockout and point-mutation cell models; allosteric activator treatment |
| CHN1 | Neurodevelopmental disorders | Knockout and overexpression in neuronal cells |
| UNC13A | Neurodegeneration | Knock-in of disease-associated mutations in neurons |
| PRKCE | Insulin resistance | Knockout and point-mutation in adipocytes |
| DGKA | Cancer | Knockout and overexpression in cancer cell lines |
Obesity-induced insulin resistance
The sn-1,2-DAG-PKCε signaling axis is a key driver of obesity-induced insulin resistance. DGKQ binds and phosphorylates DAG, and its allosteric activation improves insulin sensitivity in obesity models. This highlights diacylglycerol binding as a therapeutic target for metabolic disease.
Neurological disorders
DAG-binding proteins such as α1-chimaerin regulate dendritic morphology, and their dysfunction is linked to neurodevelopmental disorders. Munc13-1, a DAG-activated protein, is essential for synaptic vesicle priming, and mutations in UNC13A are associated with neurodegenerative diseases.
Cancer
Diacylglycerol kinases and protein kinase C isoforms are frequently dysregulated in cancer. DAG binding regulates their activity, influencing cell proliferation, survival, and migration. Targeting DAG-binding domains is a potential anticancer strategy.
From diacylglycerol binding-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of DAG binding affect insulin signaling? | DGKQ knockout or point-mutation cell lines |
| How does DAG binding regulate neuronal morphology? | CHN1 knockout and overexpression in primary neurons |
| What is the role of DAG binding in synaptic transmission? | UNC13A knock-in of DAG-binding mutations |
| Does DAG binding to perilipin 3 control lipid storage? | PLIN3 knockout and tagged knock-in in adipocytes |
| Can allosteric modulators alter DAG binding? | Point mutations in DGKQ allosteric site |
| Which DAG-binding proteins are essential for cancer growth? | CRISPR library screening in cancer cells |
How to Study the diacylglycerol binding Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Lipid overlay assay | Binding of proteins to immobilized DAG | Identify DAG-binding domains |
| Surface plasmon resonance | Real-time binding kinetics | Quantify affinity for DAG |
| Fluorescence microscopy | Subcellular localization of DAG sensors | Live-cell imaging of DAG dynamics |
| CRISPR knockout screen | Gene requirement for DAG signaling | Discover novel DAG-binding proteins |
| DGK activity assay | Conversion of DAG to phosphatidic acid | Measure enzyme function |
| Isothermal titration calorimetry | Thermodynamics of DAG binding | Characterize binding affinity |
| Proteomics | Protein interactions with DAG | Identify DAG-binding complexes |
Measuring DAG binding in vitro
Recombinant DAG-binding domains can be assayed for binding to DAG-containing liposomes or immobilized DAG. Methods include surface plasmon resonance, isothermal titration calorimetry, and fluorescence polarization.
Cellular imaging of DAG binding
Genetically encoded DAG sensors (e.g., C1 domain-GFP) allow real-time visualization of DAG dynamics in live cells. This can be combined with confocal or TIRF microscopy to study membrane recruitment.
Genetic screens for DAG-binding proteins
CRISPR knockout libraries can be screened for genes that affect DAG signaling or DAG-dependent phenotypes. Bioinformatics analysis of screen hits can identify novel DAG-binding proteins.
Biochemical assays for DAG kinase activity
Diacylglycerol kinase activity can be measured using radioactive or fluorescent DAG substrates, and binding affinity can be determined by lipid overlay assays.
How CRISPR Can Be Used to Study GO:0019992 diacylglycerol binding
Knockout
CRISPR knockout of genes encoding DAG-binding proteins (e.g., DGKQ, CHN1) can reveal their roles in cellular signaling and disease. For example, DGKQ knockout cells show altered insulin signaling.
Point Mutation
Introducing point mutations in DAG-binding domains (e.g., C1 domain) can abolish DAG binding without affecting protein expression, allowing precise dissection of binding-dependent functions.
Knock-in
Knock-in of disease-associated mutations or tagged versions of DAG-binding proteins (e.g., GFP-tagged PLIN3) enables tracking and functional studies in physiological contexts.
Overexpression
Overexpression of DAG-binding proteins or their domains can amplify signaling and reveal gain-of-function phenotypes, such as enhanced dendritic growth by α1-chimaerin.
How EDITGENE Supports diacylglycerol binding Research
Researchers studying diacylglycerol binding-related genes often need to determine whether a candidate gene is causally involved in a specific signaling pathway or disease. EDITGENE provides comprehensive CRISPR-based services to accelerate this discovery.
Contact EDITGENE today to design your custom CRISPR model for diacylglycerol binding research.
Frequently Asked Questions About diacylglycerol binding
What is diacylglycerol binding?
Diacylglycerol binding is a molecular function (GO:0019992) where a protein interacts with diacylglycerol, a lipid second messenger, typically via specialized domains like the C1 domain.
What genes are involved in diacylglycerol binding?
Genes encoding diacylglycerol kinases (DGKA, DGKQ, DGKZ), protein kinase C isoforms (PRKCA, PRKCE), chimaerins (CHN1, CHN2), Munc13 (UNC13A, UNC13B), and perilipins (PLIN3) are key examples.
What is the C1 domain?
The C1 domain is a protein module that binds diacylglycerol and phorbol esters, found in protein kinase C, chimaerins, and RasGRPs.
How does diacylglycerol binding regulate insulin sensitivity?
DAG binding to DGKQ and PKCε modulates the sn-1,2-DAG-PKCε axis; allosteric activation of DGKQ improves insulin resistance in obesity models.
What diseases are associated with diacylglycerol binding?
Obesity-induced insulin resistance, cancer, and neurological disorders have been linked to dysregulated DAG binding.
How can I study diacylglycerol binding in the lab?
Common methods include lipid overlay assays, surface plasmon resonance, fluorescence microscopy with DAG sensors, and CRISPR screens.
What is the role of diacylglycerol kinase in DAG binding?
Diacylglycerol kinases bind DAG and phosphorylate it to phosphatidic acid, terminating DAG signaling.
Can CRISPR be used to study diacylglycerol binding?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models allow precise interrogation of DAG-binding proteins.
What is the PAT domain?
The PAT domain is a conserved region in perilipins that mediates DAG binding and lipid droplet association.
How does Munc13-1 bind diacylglycerol?
Munc13-1 contains a C1 domain that binds DAG, and this interaction is required for synaptic vesicle priming.
Conclusion
Diacylglycerol binding (GO:0019992) is a fundamental molecular function that underpins lipid second messenger signaling in health and disease. The diversity of DAG-binding proteins and their roles in insulin resistance, neuronal function, and cancer make this term a rich area for research. CRISPR-based models and EDITGENE services can accelerate the functional dissection of DAG-binding proteins and their therapeutic potential.
References
- 1. Zambo B et al.. 2024. Comparative analysis of PDZ-binding motifs in the diacylglycerol kinase family.. FEBS J 291(4):690-704 PMID: 37942667
- 2. Zheng ZG et al.. 2023. Discovery of a potent allosteric activator of DGKQ that ameliorates obesity-induced insulin resistance via the sn-1,2-DAG-PKCε signaling axis.. Cell Metab 35(1):101-117.e11 PMID: 36525963
- 3. Colón-González F et al.. 2006. C1 domains exposed: from diacylglycerol binding to protein-protein interactions.. Biochim Biophys Acta 1761(8):827-37 PMID: 16861033
- 4. Stribny J et al.. 2023. Binding of perilipin 3 to membranes containing diacylglycerol is mediated by conserved residues within its PAT domain.. J Biol Chem 299(12):105384 PMID: 37898398
- 5. Tu-Sekine B et al.. 2017. Measuring Diacylglycerol Kinase-θ Activity and Binding.. Methods Enzymol 583:231-253 PMID: 28063493
- 6. van Blitterswijk WJ et al.. 1999. Diacylglycerol kinases in signal transduction.. Chem Phys Lipids 98(1-2):95-108 PMID: 10358932
- 7. Buttery P et al.. 2006. The diacylglycerol-binding protein alpha1-chimaerin regulates dendritic morphology.. Proc Natl Acad Sci U S A 103(6):1924-9 PMID: 16446429
- 8. Das J et al.. 2023. Activation of Munc13-1 by Diacylglycerol (DAG)-Lactones.. Biochemistry 62(18):2717-2726 PMID: 37651159
